香港股市 已收市

MRK Jun 2024 140.000 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
1.7900-0.1000 (-5.29%)
收市:01:45PM EST
全螢幕
前收市價1.8900
開市1.9900
買盤1.8200
賣出價1.9000
拍板140.00
到期日2024-06-21
今日波幅1.7900 - 1.9900
合同範圍
成交量42
未平倉合約1.19k
  • Reuters

    New York attorney general urges stronger safety warning on asthma drug Singulair

    The attorney general for one of the most populous U.S. states this week urged federal drug regulators to address safety risks associated with the widely used asthma and allergy medicine Singulair, saying current warnings on the drug's packaging are insufficient, particularly for children. In a letter dated on Wednesday, the New York state attorney general's office urged the U.S. Food and Drug Administration to further investigate and warn consumers and healthcare providers about harmful neuropsychiatric side effects of Singulair, also known by its generic name montelukast. The office told the FDA that the effects of Singulair on children are a "particularly urgent concern in light of the national youth mental health crisis plaguing our state."

  • Insider Monkey

    20 Fastest Growing Biotech Companies in the US

    In this article, we will be taking a look at the 20 fastest growing biotech companies in the US. If you are not interested in learning about the landscape of biotech companies, head straight to the 5 Fastest Growing Biotech Companies In The US. The biotechnology sector in the United States is witnessing a surge […]

  • infocast

    科倫博泰生物(06990)將收取默沙東7500萬美元臨床里程碑付款

    科倫博泰生物(06990)提供有關集團與默沙東就公司核心產品SKB264(亦稱為MK-2870)合作的最新情況。截至公告日期,默沙東已啟動3項關鍵3期臨床試驗,評估SKB264(MK-2870)作為單藥用於治療既往接受過治療的具有表皮生長因子受體(EGFR)突變或其他基因組改變的晚期或轉移性非小細胞肺癌(NSCLC),作為單藥用於治療既往接受含鉑化療及免疫治療的子宮內膜癌(EC),以及與帕博利珠單抗聯合用於程序性死亡配體1(PD-L1)表達大於或等於50%的轉移性NSCLC。根據許可及合作協議以及默沙東的書面確認,上述NSCLC及EC的臨床試驗已觸發相關臨床里程碑付款,總金額為7500萬美元。公司已收到默沙東的部分付款,並預計在不久的將來收到餘下款項。(ST)